Intraperitoneal and intravenous paclitaxel plus S-1 in patients with gastric cancer with peritoneal metastasis - Intraperitoneal and intravenous paclitaxel plus S-1 in patients with gastric cancer with peritoneal metastasis

Fujiwara Yoshiyuki0 个研究点目标入组 50 人开始时间: 2018年12月7日最近更新: 2023年10月17日

适应症

试验速览

暂无简介。

•1) histologically proven primar gastric adenocarcinoma.
•2) Peritneal metastasis and/or cancer cells on peritoneal cytology.
•3) Patients with following adequate function of important organs at screening period.
•Neutrocyte >= 1,000/mm3
•Hemoglobin >= 8.0g/dl
•Platelet >= 75,000/mm3
•AST, ALT < 150U/L
•Total Bilirubin <= 3.0mg/dL
•Creatinine clearance >= 30ml/min
•4) Eastern Cooperative Oncology Group performance status 0-2
•5) Age >= 20, < 85 years
•6) Written informed consent.

•1)The absence of metastasis to distant organ sites except the retroperitoneum, ovary and abdominal lymph nodes.
•2)Contraindication to S-1 or paclitaxel.
•3)Apparent infection or inflammation.
•4)Sever heart disease.
•5)Sever complication.
•6)Gastrointestinal bleeding requiring blood transfusion repeatedly.
•7)Pregnancy, breast feeding or intention to become pregnant.
•8)Inappropriate for this trial for other reasons.

发起方

Fujiwara Yoshiyuki